Table 2.

Key ongoing studies of new therapeutics in metastatic colorectal cancer.

Phase	Treatment arms (therapeutic target)	Primary end points	Trial identifier
III	Nintedanib (VEGFR, FGFR, PDGFR) vs. placebo	PFS, OS	LUME-Colon1 NCT02149108
II	Sym004 (EGFR) vs. investigator’s choice therapy	OS	NCT02083653
II	Irinotecan-cetuximab ± vemurafenib (BRAF)	PFS	SWOG 1406 NCT02164916
II	Panitumumab + dabrafenib (BRAF) + trametinib (MEK)	RR, PFS	NCT01750918
II	Cetuximab + aleplisib (PI3K) + encorafenib (BRAF)	PFS	NCT01719380
II	T-DM1 (HER2) after progression on trastuzumab-lapatinib	RR	HERACLES-RESCUE EudraCT 2015–003275–30
II	Pembrolizumab (PD-1)	RR	KEYNOTE-164 NCT02460198
II	Ipilimumab (CTLA-4) + nivolumab (PD-1)	RR	CheckMate-142 NCT02060188
III	MABp1 (Xilonix™; IL-1α) vs. placebo	OS	XCITE NCT01767857
III	BBI-608 (STAT3, β-catenin, Nanog) + BSC vs. placebo +BSC	OS	NCT01830621
II	FOLFOXIRI-bevacizumab (concurrent vs. sequential) vs. FOLFOX-bevacizumab	ORR1	STEAM NCT01765582
		PFS1